On October 25, 2019 SRI researchers reported it will present data from multiple programs exploring novel approaches to cancer drug targeting and delivery (Press release, SRI International, OCT 25, 2019, View Source [SID1234548674]). This includes a novel technology that leverages the immune system in a new way – by tricking it into thinking cancer cells are infected with a serious virus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract C018. Primary tumor data analysis reveals novel synthetic lethal dependencies between KRAS mutation and the spliceosome
Date/Time: Tuesday, October 29, 12:30 p.m. ET
Hall D, Hynes Convention Center

Abstract 467. Cancer-Specific Intracellular Delivery of Therapeutic Antibodies Against RAS
Date/Time: Tuesday, October 29, 12:30 p.m. ET
Hall D, Hynes Convention Center

Abstract 463. A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer
Date/Time: Monday, October 28, 12:30 p.m. ET
Hall D, Hynes Convention Center